Gilead to Buy Arcellx for $7.8 B Cash at 68% Premium, Adds $5 CVR
Gilead Sciences will acquire Arcellx for $7.8 billion in cash at $115 per share, reflecting a 68% premium to its 30-day volume-weighted average price. The deal includes a $5-per-share contingent value right if Arcellx’s lead CAR-T therapy anito-cel achieves $6 billion in sales by end-2029 and is set to close in Q2 2026.
1. Deal Terms
Gilead will pay $115 per Arcellx share in cash, valuing the entire transaction at approximately $7.8 billion and representing a 68% premium to Arcellx’s 30-day volume-weighted average price. This upfront payment ensures immediate value for Arcellx shareholders upon closing.
2. Contingent Value Right Structure
Shareholders will receive an additional $5 per share via a contingent value right if anito-cel, Arcellx’s BCMA-directed CAR-T therapy, reaches $6 billion in cumulative global net sales by December 31, 2029. This performance-based incentive aligns future upside with commercial success in multiple myeloma.
3. Expected Timeline
The acquisition is anticipated to close in the second quarter of 2026, pending approval from Arcellx shareholders and customary regulatory clearances. Integration planning is already underway to ensure a smooth transition of the CAR-T programs into Gilead’s operations.
4. Strategic Impact
The deal bolsters Gilead’s oncology portfolio by adding a late-stage CAR-T candidate targeting multiple myeloma, positioning it to compete more directly with Johnson & Johnson. It also deepens the companies’ existing BCMA-CAR-T collaboration and accelerates Gilead’s entry into the fast-growing cell therapy market.